Ironwood Pharmaceuticals (IRWD) : During the past 4 weeks, traders have been relatively bearish on Ironwood Pharmaceuticals (IRWD), hence the stock is down -2.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.28% relative to the S&P 500. The 4-week change in the price of the stock is -1.84% and the stock has fallen -0.22% in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.39% and the 50-Day Moving Average is 0.76%. Ironwood Pharmaceuticals (NASDAQ:IRWD): stock turned positive on Friday. Though the stock opened at $13.31, the bulls momentum made the stock top out at $13.44 level for the day. The stock recorded a low of $12.8418 and closed the trading day at $13.36, in the green by 0.15%. The total traded volume for the day was 671,771. The stock had closed at $13.34 in the previous days trading.
The company Insiders own 7.17% of Ironwood Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.38% . Institutional Investors own 97.1% of Ironwood Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 18.09%. Also, Barclays maintains its view on Ironwood Pharmaceuticals (NASDAQ:IRWD) according to the research report released by the firm to its investors. The shares have now been rated Equal-weight by the stock experts at the ratings house. Barclays raises the price target from $11 per share to $12 per share on Ironwood Pharmaceuticals . The rating by the firm was issued on August 5, 2016.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.